Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 219-225 , May 2011

Targeting Parathyroid Hormone Level in Diabetic Patients With Stage 3 to 5 Chronic Kidney Disease: Does Metabolic Syndrome Matter?

  • Rengin Elsurer, MD

      Affiliations

    • Department of Nephrology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey
    • Corresponding Author InformationAddress reprint requests to Rengin Elsurer, MD, Kultur Mah. Caldiran Sok Dogan Apt. 34/18, 06420 Kolej, Ankara ,Turkey.
  • ,
  • Baris Afsar, MD

      Affiliations

    • Department of Nephrology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey
  • ,
  • Ertugrul Guner, MD

      Affiliations

    • Department of Internal Medicine, Zonguldak Ataturk State Hospital, Zonguldak, Turkey
  • ,
  • Idris Yildiz, MD

      Affiliations

    • Department of Internal Medicine, Zonguldak Ataturk State Hospital, Zonguldak, Turkey

References 

  1. Reis JP, von Mühlen D, Miller ER. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol. 2008;159:41–48
  2. Reis JP, von Mühlen D, Kritz-Silverstein D, et al. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community dwelling older adults. Diabetes Care. 2007;30:1549–1555
  3. Inaba M, Okuno S, Nagasue K, et al. Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am J Kidney Dis. 2001;38:S139–S142
  4. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  5. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266
  8. Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int. 1993;44:159–164
  9. Takahashi N, Kojima T, Ogawa H, et al. Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients. Nephrology (Carlton). 2007;12:539–545
  10. Hjelmesaeth J, Hofsø D, Aasheim ET, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol. 2009;8:7
  11. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol. 2004;151:167–172
  12. Reinehr T, de Sousa G, Alexy U, et al. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol. 2007;157:225–232
  13. Jorde R, Sundsfjord J, Haug E, et al. Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension. 2000;35:1154–1159
  14. Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens. 2005;23:1639–1644
  15. Lippi G, Montagnana M, Targher G, et al. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults: response to Reis, et al. Diabetes Care. 2007;30:e135
  16. Inukai T, Fujiwara Y, Tayama K, et al. Alterations in serum levels of 1 alpha,25(OH)2 D3 and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract. 1997;38:53–59

PII: S1051-2276(10)00109-3

doi: 10.1053/j.jrn.2010.04.006

Journal of Renal Nutrition
Volume 21, Issue 3 , Pages 219-225 , May 2011